This promotional meeting was fully funded and organized by MSD UK
Prescribing information and adverse events reporting are found at the bottom of the page for UK Healthcare Professionals only
KEYTRUDA▼ (pembrolizumab) as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy. KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a combined positive score (CPS) ≥ 10
KeyFocus Bladder 2018 was a promotional medical educational event that was held in London on June 2018. MSD collaborated with a renowned academic panel of clinicians who specialize in urothelial carcinoma, to shape an agenda which would allow us to provide valued education on all aspects of urothelial carcinoma, looking at the management of patients across the entire pathway.
Please contact us if you would like to know more about our upcoming urothelial carcinoma medical education events: email@example.com
Urothelial Cancer: the present and the future
“We need to keep talking about bladder cancer, working together and building new networks.” Prof. Robert Jones summarizes the issues in the current landscape plus key learnings and future innovations presented by the oncology experts at KEYFOCUS Bladder Cancer 2018.
The role of chemotherapy in an era of immunotherapies
With the rise of novel immunotherapies, the role of chemotherapy is being challenged as we look for a solution that can improve outcomes with minimal toxicity. Dr Maria de Santis believes that although the landscape is changing, chemotherapy still plays a vital role in advanced urothelial carcinoma.
Cystectomy or radiotherapy? New data for MIBC
While cystectomy has become the standard therapy in the treatment of muscle-invasive bladder cancer, radiotherapy is being seen as a potential option owing to its low toxicity, efficacy in disease control, while maintaining quality of life. Prof. Robert Huddart presents the case for radiotherapy.
Rare bladder cancers: challenges & issues
Rare bladder and urinary tract tumours have a scarcity of robust efficacy data, and a lack of consensus on treatment approach can prove challenging for oncolologists. Prof. Syed Hussain discusses how greater national and international collaboration can help when striving to improve treatment outcomes.
Controversial issues in bladder cancer: the experts’ discussion
Led by Prof. Robert Jones, Prof. Winald Gerritsen, Dr Simon Crabb and Mr Hugh Mostafid discuss key issues in bladder cancer management and treatment, including diagnostic pathways, multi-disciplinary approaches, and selection criteria for immunotherapy, radiotherapy, or surgery.
Webcasts now available!
To learn more about bladder cancer, different treatment approaches and rare types of bladder cancer, watch the full presentations from the meeting.
Adverse events ahould be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to MSD (Tel: 01992 467272), UK.
DOP December 2018
This link takes you to a promotional website sponsored by MSD